Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5M | 5M | 4M | 111K | 111K |
| Gross Profit | 2M | 2M | 2M | 19K | 19K |
| Operating Income | -4M | -6M | -5M | -5M | -325K |
| EBITDA | -3M | -7M | -4M | -5M | -2M |
| Net Income | -4M | -8M | -5M | -2M | -325K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.02
+0.00% today
1Y Change
+15.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Red Light Holland Corp. (TRUFF) is a Healthcare stock with a market cap of $20.00M and listed on OTC. The stock last traded around $0.02 and up 15.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +4.0%, EPS growth of +47.7%, a dividend yield of 0.0%. What stands out right now is revenue +4.0%, EPS +47.7%, free cash flow +48.6% with operating margin -100.4% and ROIC -24.6%. Valuation sits in the middle of the pack at price/sales 4.1. Stock Foundry combines TRUFF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRUFF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TRUFF Max Drawdown
-72.50%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TRUFF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$111.0K
+0.0% YoY
FY Net Income
-$325.2K
+80.2% YoY
Free Cash Flow
-$506.3K
+86.0% YoY
Revenue Growth
+4.0%
EPS Growth
+47.7%
Gross Margin
30.5%
Net Margin
-114.5%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5M | 5M | 4M | 111K | 111K |
| Gross Profit | 2M | 2M | 2M | 19K | 19K |
| Operating Income | -4M | -6M | -5M | -5M | -325K |
| EBITDA | -3M | -7M | -4M | -5M | -2M |
| Net Income | -4M | -8M | -5M | -2M | -325K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 12M | 14M | 18M | 31M | 2M |
| Total Assets | 21M | 24M | 30M | 36M | 4M |
| Total Liabilities | 4M | 4M | 4M | 2M | 5M |
| Shareholder Equity | 17M | 20M | 26M | 34M | -1M |
| Total Debt | 2M | 2M | 2M | 866K | 87K |
| Net Debt | -10M | -12M | -17M | -30M | -2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
238K
+92.9% YoY
Capital Expenditures
268K
+0.0% YoY
Free Cash Flow
506K
+86.0% YoY
Key ratios
Gross Margin
30.5%
Operating Margin
-100.4%
Net Margin
-114.5%
ROE
-29.6%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.